Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (4834)	11/22/1997 2:06:00 PM
From: Pseudo Biologist	Read Replies (1) \| Respond to of 17367

Robert, on Giroir my story comes from a former Xomite (not Harmon), and his (biased?, selective?, accurate?) recollection is that Giroir learned of Xoma's involvement with BPI and approached Xoma to convince them to let him use it for meningoccemia (sp?). The FDA stuff has been discussed in other threads by the usual suspects (chirodoc, Andy, etc); yes, it is good, especially if the drug works. On IDEC, Hecht of Merryl-Lynch thinks Rituxan (and Y2B8; the mouse, radiolabeled version) has a market potential of over $500 mill per year. Thanks for the other information, PB

To: Robert K. who wrote (4834)	11/22/1997 2:43:00 PM
From: Andrew H	Respond to of 17367

Robert, I cannot follow some of the mental jumps you are making. I have not really been involved in the giroir/BPI for meningitis discussion. >>Cant believe the fda story hasnt been discussed yet. DUH. Are you folks all brain dead or am I nuts again. Perhaps both :-) -speed through life saving drugs -drugs for kids.......................................Think on it.<< Could you please elaborate a bit on this? I am not clear what you are saying. But the "both" comment is most likely accurate. (:>)